Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-04-19
2005-04-19
Ungar, Susan (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S134100, C424S135100, C424S138100, C424S139100, C424S141100, C424S184100, C530S387100, C530S387300, C530S387700, C530S387900, C530S388100
Reexamination Certificate
active
06881405
ABSTRACT:
The invention is an apparatus and method for the treatment of prostate cancer, and involves administering an antibody that specifically binds with prostate antigen.
REFERENCES:
patent: 3865689 (1975-02-01), Goldenberg
patent: 4331647 (1982-05-01), Goldenberg
patent: 4446122 (1984-05-01), Chu et al.
patent: 5053224 (1991-10-01), Koprowski et al.
patent: 5165922 (1992-11-01), Hellstrom et al.
patent: 5459043 (1995-10-01), Brown
patent: 5639621 (1997-06-01), Bosslet et al.
patent: 5683674 (1997-11-01), Taylor-Papadimitriou et al.
patent: 5773292 (1998-06-01), Bander
patent: 5849876 (1998-12-01), Linsley et al.
patent: 0 234 122 (1987-09-01), None
patent: 0 308 208 (1989-03-01), None
patent: 0 652 014 (1995-05-01), None
patent: 0 652 014 (1995-10-01), None
patent: WO 8700053 (1987-01-01), None
patent: WO 8803954 (1988-06-01), None
patent: WO 8905140 (1989-06-01), None
patent: WO9104490 (1991-04-01), None
patent: WO9729199 (1997-08-01), None
patent: WO9736021 (1997-08-01), None
patent: WO9810292 (1998-03-01), None
Meyers et al, 1989, Prostate, 14(3): 209-20.*
Accession No. A26757, genBank, MPSRC/4 pp. 1-3, 1987.*
Ma suzawa, M. Neuro Sci. Res 18(1):27-34, 1993.*
Sherman , LA . Crit. Rev. Immunol. 18(1-2):47-54, 1998.*
Smith, MD. Clin. Immunol. 41:841-850, 1994.*
Stites etal (eds.), Med. Immunol. Appleton & Lange, Connecticut, p. 103, 1997.*
Abbas AK et al., “Antigen presentation by B lymphocytes,”Antigen Presenting Cells: Diversity, Differentiation, and Regulation269-279 (1988).
Adams S et al., “Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings,”Eur J Nucl Med. 25(9):1277-83 (1998).
Alzona M et al., “IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells,”J Immunol. 154(1):9-16 (1995).
American Cancer Society, “Cancer Facts and Figures,” Atlanta, GA: American Cancer Society (1995).
Andersson K et al., “Modulation of antigen-antibody complexations by immunoglobulins,”Scand J Immunol. 42(4):407-17 (1995).
Bachmann MF et al., “Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen,”Eur J Immunol. 24(10):2567-70 (1994).
Barnd DL et al., “Specific, major histocompatibility complex-unrestricted recognition of tumor associated mucins by human cytotoxic T cells,”Proc Natl Acad Sci U S A. 86(18):7159-63 (1989).
Bartoloni C et al., “Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage III and IV melanoma and chronic inflammatory bowel disease patients,”Oncology50(1):27-34 (1993).
Bast RC Jr. et al., “A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer,”New England J. Med. 309(15):883-7 (1983).
Baum RP et al., “Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma,”Cancer73(3 Suppl):1121-5 (1994).
Bernard NF et al., “Possible Role for Specific Surface Immunoglobulin In Antigen Presentation,”Antigen Presenting Cells: Diversity, Differentiation, and Regulation291-300 (1988).
Boon T et al., “Tumor antigens recognized by T lymphocytes,”Annu Rev Immunol. 12:337-65 (1994).
Brakenhoff RH et al., “Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer,”Cancer Immunol Immunother. 40(3):191-200 (1995).
Bretscher PA et al., “Establishment of stable, cell-mediated immunity that makes “susceptible” mice resistant to Leishmania major,”Science257(5069):539-42 (1992).
Brockmeyer NH et al., “Immunomodulation of cimetidine in healthy volunteers,”Klin Wochenschr. 67(1):26-30 (1989).
Bouige P et al., “Immune complexes as immunizing agents to increase the number of monoclonal antibody producing hybrids and to deviate the response to poorly immunogenic epitopes,”Hybridoma9(6):519-26 (1990).
Bukowski RM et al., “Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies,”J Immunother. 10(6):432-9 (1991).
Canevari S et al., “Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody,”J Natl Cancer Inst. 87(19):1463-9 (1995).
Chang CT et al., “Circular dichroic analysis of protein conformation: inclusion of the beta-turns,”Anal Biochem. 91(1):13-31 (1978).
Chatterjee MB et al., “Idiotypic antibody immunotherapy of cancer,”Cancer Immunol Immunother. 38(2):75-82 (1994).
Chester SJ et al., “Improved detection of the early stages of colon cancer by determining both free circulating and immune complex-bound antigens reactive with monoclonal antibody,”Cancer Res. 54(15):3974-8 (1994).
Cheung NK et al., “Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival,”Cancer Res. 54(8):2228-33 (1994).
Clarke-Pearson DL et al., “Palliative surgery for epothelial ovarian cancer,” In Rub SC, Sutton GP eds.Ovarian CancerNew York: McGraw-Hill, Inc. 1993: 351-364.
Crum Ed, “Effect of cisplatin upon expression of in vivo immune tumor resistance,”Cancer Immunol Immunother. 36(1):18-24 (1993).
Defoin A et al., “A new liquid phase actinometer: Quantum yield and photo-cidnp study of phenylglyoxylic acid in aqueous solution,”J. Photochem. 33:237-255 (1985).
DiLeo AJ et al., “High resolution removal of virus from protein solutions using a membrane of unique structure,”Biotechnology10(2):182-8 (1992).
DiLeo AJ et al., “Size exclusion removal of model mammalian viruses using a unique membrane system, Part II: Module qualification and process simulation,”Biologicals21(3):287-96 (1993).
DiLeo AJ et al., “Sixe exclusion removal of model mammalian viruses using a unique membrane system, Part I: Membrane qualification,”Biologicals21(3):275-86 (1993).
Dorai, H et al., “Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function,”Hybridoma10:211-7 (1991).
Dohlsten M et al., “Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy,”Proc Natl Acad Sci U S A. 91(19):8945-9 (1994).
Dohlsten M et al., “Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo,”Proc Natl Acad Sci U S A. 92(21):9791-5 (1995).
Donnerstag B et al., “Immunological profile of patients with ovarian cancer under immunostimulation with murine monoclonal antibodies,”International J. of Oncology6:853-858 (1995).
Durrant LG et al., “Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7,”Cancer Res. 54(18):4837-40 (1994).
Ehrke MJ et al., “Effects of anticancer drugs on the immune system in humans,”Semin Oncol. 16(3):230-5 (1989).
Engvall E and Perlman P, “Enzyme-linked immunosorbent assay (ELISA), Quantitative assay of immunoglobulin G.”Immunochemistry8:871 (1971).
Fagerberg J et al., “Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?,”Cancer Immunol Immunother. 37(4):264-70 (1993).
Fagerberg J et al., “Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?,”Cancer Immunol. Immunother. 38(3):149-59 (1994).
Fagerberg Jet al., “Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes,”Cancer Res. 55(
Leveugle Beatrice
Madiyalakan Ragupathy
Noujaim Antoine A.
Schultes Birgit
AltaRex Medical Corp.
Davis Minh-Tam
Ropes & Gray LLP
Ungar Susan
LandOfFree
Reagents and methods for inducing an immune response to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reagents and methods for inducing an immune response to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reagents and methods for inducing an immune response to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3402451